The Highest-Beta Name in Big Tech Just Ran. Here’s the Risk
Arm just posted a 187% year-to-date run on the back of real AI demand, but a beta of 3.89 turns every market hiccup into a violent swing, and the stock has already priced in a lot of good news. The…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Arm Holdings (NASDAQ:ARM | ARM Price Prediction) climbed 7.48% in today’s session and now trades near $314.71. Our 24/7 Wall St. price target for Arm is $290.01 over the next 12 months, which implies -7.85% downside.
| Metric | Value |
|---|---|
| Current Price | $314.71 |
| 24/7 Wall St. Price Target | $290.01 |
| Upside/Downside | -7.85% |
| Rating | HOLD |
| Confidence Level | 90% |
Our model rates Arm a hold with high confidence. Fundamentals look strong. Price is the concern: at a beta of 3.89, Arm moves far more sharply than the broader market in both directions, and the stock has already priced in a lot of good news.
Why We Could Be Wrong
Our target sits below the current price, and Arm has real catalysts. Management says demand for its Arm AGI CPU now exceeds $2 billion, and data center royalties more than doubled year over year again.
A faster silicon ramp could prove the model too cautious. Treat the 24/7 Wall St. price target as one datapoint among many. A full bull case follows below.
A 187% Year-to-Date Run Powered by Revenue Growth
Arm is up 187.45% year to date, 33.81% over the past month and 2.57% over the past week. The shares remain about 30% below the 52-week high of $452.70 and roughly 215% above the low of $100.02.
In Q1 FY2027, revenue reached $1.289B, up 22.4% and ahead of estimates. GAAP EPS of $0.25 missed expectations, while non-GAAP EPS of 45 cents came in above the high end of guidance. For Q2, management guided to revenue of $1.38 billion, plus or minus $50 million.
Why Bulls See $424 Ahead
Our bull case reaches $423.70. Getting there depends on the AGI CPU, Armv9 royalty mix and hyperscaler adoption. NVIDIA (NASDAQ:NVDA) Vera and custom CPUs from other major hyperscalers all run on Arm.
Management also sees the CPU market growing beyond $100 billion-plus. Analysts lean bullish: 27 rate the stock a Buy or Strong Buy, against only 2 Sell ratings.
What a 3.89 Beta Means on the Way Down
Our bear case falls to $230.01. The consensus analyst target of $288.70 already trails the stock. First-generation AGI CPU gross margins are expected in the high 30% range, maybe low 40s, well below the IP model’s 92.48% gross margin.
Other risks include the Qualcomm (NASDAQ:QCOM) litigation trial in Q4 2026, dependence on Arm China and smartphone weakness. As a counterpoint, much of the GAAP margin compression traces to R&D spending of $838M and stock-based compensation of $343M. That spending funds future growth.
Arm Trades at a Steep Premium to NVIDIA and Qualcomm
NVIDIA is a key Arm customer through Vera. It trades at 46x trailing earnings while revenue grew 105.85%.
Qualcomm is both a licensing-model peer and Arm’s litigation opponent, and it trades at 35x earnings.
Broadcom (NASDAQ:AVGO) competes for custom AI silicon spending and grew AI revenue 221%.
| Company | Trailing P/E | P/FCF |
|---|---|---|
| Arm | 345x | 319x |
| NVIDIA | 46x | 58x |
| Qualcomm | 35x | 15x |
Next to its peers, our target looks reasonable or even generous.
Arm Price Prediction 2026-2030
My view: the 24/7 Wall St. price target of $290.01 and hold rating hold up with 90% confidence. Valuation is the deciding factor.
The case gets stronger if Arm’s Q3 update shows AGI CPU demand turning into revenue above $1 billion. It weakens if royalty growth stalls in the high teens. At 129x forward earnings, the valuation leaves little room for error until earnings catch up.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $317.66 |
| 2027 | $294.10 |
| 2028 | $265.80 |
| 2029 | $277.06 |
| 2030 | $293.50 |
These projections assume Arm keeps executing its current strategy. The 2030 bull case reaches $595.89 if the silicon business scales.
Contact [email protected] for any questions or corrections.



